CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Edesa Biotech Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Edesa Biotech Inc
100 Spy Crt
Phone: (905) 475-1234p:905 475-1234 Markham, ON  L3R 5H6  Canada Ticker: EDSAEDSA
Business Summary
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome, a life-threatening form of respiratory failure. EB05 has also been included in a United States government funded platform study of host directed therapeutics. It has received Canadian regulatory approval to conduct a Phase II trial its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. It is developing an sPLA2 inhibitor, EB01 (1.0% daniluromer cream), as a topical treatment for chronic Allergic Contact Dermatitis, a common occupational skin condition.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20249/30/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board CarloSistilli 67 5/23/2023 6/7/2019
President Michael J.Brooks 45 6/7/2019 6/7/2019
Chief Executive Officer, Corporate Secretary, Director PardeepNijhawan 53 6/7/2019 6/7/2019
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CAG Capital Inc.
China Growth Capital Inc
Edesa Biotech Research, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 16 (As of 12/15/2023)
Outstanding Shares: 3,247,389 (As of 8/9/2024)
Shareholders: 13
Stock Exchange: NASD
Fax Number: (905) 475-1234


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024